Japanese Journal of Clinical Oncology · 2009 · 40 citations · 40 references
MedicineOncologyPharmacologyApoptosisChemotherapyMolecular OncologyChemotherapy ResistanceCytotoxic ChemotherapyAndrogen Receptor ExpressionAnticancer ChemotherapyBreast Cancer ChemotherapyChemotherapy Response AssessmentImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical Staining
OBJECTIVE: The purpose of this study was to evaluate the impact of various pathologic and biologic factors in triple-negative breast cancer (TNBC) on chemotherapy response using in vitro ATP-based chemotherapy response assay (ATP-CRA). METHODS: Forty-seven cases of TNBC were included. Immunohistochemical stains for androgen receptor (AR), p53, CD10, c-kit, CK5/6, vimentin, bcl-2, E-cadherin, Ki-67 and epidermal growth factor receptor were performed. In vitro ATP-CRA was used to analyze chemosensitivity for 5-fluorouracil (5-FU), docetaxel, doxorubicin, epirubicin, vinorelbine, gemcitabine, methotrexate (MTX), oxaliplatin and paclitaxel. RESULTS: The results showed that all cytotoxic agents demonstrated the trend that E-cadherin-expressing cases had a higher cell death rate than E-cadherin-negative cases. Particularly, vinorelbine showed statistical significance (P = 0.004). Cases with AR expression showed higher cell death rates than those without in 5-FU and MTX (P = 0.012 and 0.014, respectively). CONCLUSIONS: E-cadherin and AR could be candidate predictive factors for chemotherapy response in TNBC. Further in vivo study is required to clarify their roles.
40
Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Lisa A. Carey, Elizabeth Claire Dees, Lynda Sawyer et al. · Clinical Cancer Research · 2007 · 2.1K citations · Full text
Medicine, Oncology, Breast Oncology +14
Jennet Harvey, Gary M. Clark, C. Kent Osborne et al. · Journal of Clinical Oncology · 1999 · 2.1K citations
Medicine, Endocrinology, Oncology +17